Subscribe: Market Wire - Pharmaceuticals and Biotech: Trials
http://img.marketwire.com/rss/mwPBTR.rss
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
announces  cancer  cannabis  clinical  company  jul  july  marketwired jul  marketwired  media  new  otc pink  research  today 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Trials

Marketwired - Trials



Marketwired - Trials



Last Build Date: Thu, 20 Jul 2017 13:50:29 EDT

Copyright: Copyright: (C) Marketwired
 



ECPO Files Issuers Company Related Action Notification with the Financial Industry Regulatory Authority requesting Name and Symbol Change

Thu, 20 Jul 2017 13:19:52 EDT

The Company Also Updated Progress on the Validation Process for its ITV-1 Patented HIV/AIDS Treatment




SANUWAVE Appoints Alat Medika Indonesia as Distributor for dermaPACE and Liaison to Clinical Trials Participation for Company's Wound Care Product(s) in Indonesia

Thu, 20 Jul 2017 09:00:00 EDT

SUWANEE, GA--(Marketwired - Jul 20, 2017) - SANUWAVE Health, Inc. (OTCQB: SNWV) is pleased to announce that the Company has appointed Alat Medika Indonesia as distributor for dermaPACE® and liaison for clinical trials participation for Company's wound care product in Indonesia. The expected revenue from this agreement will be north of $1 million over the next three years.




Medical Marijuana Reports Record Month of Sales -- CFN Media

Thu, 20 Jul 2017 09:00:00 EDT

SEATTLE, WA--(Marketwired - Jul 20, 2017) -  CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article on Medical Marijuana Inc.'s (OTC PINK: MJNA) Kannaway® subsidiary and its record monthly sales in June.




CV Sciences, Inc. Cites Recent Clinical Study on Pharmaceutical-Grade CBD Shown to Lower Blood Pressure

Thu, 20 Jul 2017 08:45:00 EDT

Company Gaining Traction with Drug Candidate CVSI-007 to Become the Only FDA Approved Treatment for Smokeless Tobacco Addiction




Propanc Biopharma Receives Acceptance of Key Patent Application for Cancer Treatment in China

Thu, 20 Jul 2017 08:30:00 EDT

Patent covers use of a pharmaceutical composition comprising trypsinogen and chymotrypsinogen




ANGLE plc: Preclinical Study Presented At Tumor Boston Summit

Thu, 20 Jul 2017 08:15:24 EDT

GUILDFORD, UNITED KINGDOM--(Marketwired - Jul 20, 2017) - ANGLE plc (AIM: AGL) (OTCQX: ANPCY)




ORYZON to Regain Rights to ORY-1001 (RG6016)

Thu, 20 Jul 2017 07:16:55 EDT

Management to Host two Web Conferences today, July 20th

- at 10:00 am CET in Spanish and

- at 8:30 am ET in English




Clinical Teams From Top Pharma Companies Are Overcoming Challenges in Planning and Implementing Adaptive Trial Design Studies

Wed, 19 Jul 2017 19:23:00 EDT

RESEARCH TRIANGLE PARK, NC--(Marketwired - July 19, 2017) - A recent study of Top 10, Top 50, and small medical device companies found that addressing regulators' concerns for late-stage studies is the most common challenge clinical development teams encounter during their adaptive trial design preparations, according to research published by business intelligence firm Cutting Edge Information.




The Alliance for Regenerative Medicine Announces Presenting Companies at 2017 Cell & Gene Meeting on the Mesa

Wed, 19 Jul 2017 10:16:21 EDT

WASHINGTON, DC--(Marketwired - Jul 19, 2017) - The Alliance for Regenerative Medicine (ARM) today announced the initial slate of companies selected to present at its upcoming Cell & Gene Meeting on the Mesa annual conference, October 4-6, 2017.







UPDATE - Medovex Corporation Announces First Human Cases Using Its DenerveX Device and First Revenue Events

Wed, 19 Jul 2017 09:17:59 EDT

Highly Disruptive and Patented Less Invasive Device with Faster Recovery Time than Current Surgical Treatment Options for Facet Joint Syndrome




Mobile Games Provide Inroads to Cannabis Consumers -- CFN Media

Wed, 19 Jul 2017 09:13:30 EDT

SEATTLE, WA--(Marketwired - Jul 19, 2017) -  CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article taking a closer look at fully-reporting First Harvest Corp. (OTCQB: HVST) and how mobile games could help cannabis companies reach consumers in an otherwise off-limits advertising environment.




Vitality Biopharma Releases Positive Results for Treatment of Inflammatory Bowel Disease

Wed, 19 Jul 2017 09:00:00 EDT

Vitality's proprietary gut-targeted cannabosides provided marked improvement in challenging colitis efficacy model







Invictus MD Completes First Harvest & Breaks Ground on Expansion -- CFN Media

Wed, 19 Jul 2017 09:00:00 EDT

SEATTLE, WA--(Marketwired - Jul 19, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article examining Invictus MD Strategies Corp.'s (TSX VENTURE: IMH) (OTC PINK: IVITF) progress in building out its presence in Canada's licensed producer marketplace, as well as its successful ancillary businesses.




American Cannabis Company, Inc. Announces It Has Secured A Second Contract With A New Client In Arkansas

Wed, 19 Jul 2017 08:30:00 EDT

DENVER, CO--(Marketwired - Jul 19, 2017) - American Cannabis Company, Inc. (OTCQB: AMMJ) ("ACC"), a full-service business-to-business consulting solutions provider and seller of ancillary products to the cannabis industry, today announced it has secured its second client in the state of Arkansas. ACC will initially provide strategic planning and pre-licensing solutions for this new client, which include operational planning activities, facility conceptual design work and state application completion. ACC expects to leverage this contract to secure additional revenues through long-term consulting agreements and potential future sales of ancillary products.




BriaCell Provides Clinical Update on its Ongoing Phase I/IIa Clinical Study of BriaVax(TM) in Advanced Breast Cancer

Wed, 19 Jul 2017 08:30:00 EDT

BERKELEY, CA and VANCOUVER, BC--(Marketwired - July 19, 2017) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company, provided a clinical update regarding its US-based open-label Phase I/IIa clinical trial evaluating the safety and efficacy of BriaVaxT, a genetically engineered whole-cell vaccine derived from a human breast cancer cell line, to treat advanced breast cancer.




CFN Media Exclusive Interview with OWCP's Dr. Sharon Rozenblat

Wed, 19 Jul 2017 08:30:00 EDT

SEATTLE, WA--(Marketwired - Jul 19, 2017) - CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article and exclusive interview with Dr. Sharon Rozenblat, Advisory Board Member for OWC Pharmaceutical Research Corp. (OTCQB: OWCP). Dr. Rozenblat is largely responsible for the development of the company's active cannabinoid topical skin cream, and the interview focuses on that product and its potential in the rapidly growing multi-billion dollar psoriasis market.




Medovex Announces First Human Cases Using Its DenerveX Device and First Revenue Events

Wed, 19 Jul 2017 08:00:00 EDT

Highly Disruptive and Patented Less Invasive Device with Faster Recovery Time than Current Surgical Treatment Options for Facet Joint Syndrome




Emerging Issues for Pharma R&D: A Practical Approach for Pediatric Drug Programs, New Webinar Hosted by Xtalks

Wed, 19 Jul 2017 07:30:00 EDT

TORONTO, ON--(Marketwired - July 19, 2017) - In this webinar scheduled for Wednesday, August 16, 2017 at 11am EDT (4pm BST/), industry experts Dr. Barry Mangum from Paidion Research and Dr. JF Marier from Certara will discuss how pediatric considerations fit into the overall drug development program. They will also make recommendations for addressing issues from both a practical and scientific perspective. Anonymized case studies will be presented with a review of historical issues with a focus on solutions for today (i.e. licensed comparators differences in US and EU, importation issues, and endpoint selection




Medigus Expands Global Commercial Availability of MUSE Through Distribution Agreement With Izasa Hospital, S.L.U. in Spain

Wed, 19 Jul 2017 07:00:00 EDT

OMER, ISRAEL--(Marketwired - Jul 19, 2017) -  Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced a distribution agreement in Spain with Izasa Hospital, S.L.U., a distributor of medical products in the hospital sector. The five year commercialization agreement took effect July 1, 2017; Izasa Hospital, S.L.U. will be required to purchase a minimum of EUR 1.4 million of Medigus Ultrasonic Surgical Endostapler (MUSET) equipment over the course of the agreement.




Avantor Opens New Life Sciences Research Center

Tue, 18 Jul 2017 12:03:09 EDT

New Innovation Center in Bridgewater, New Jersey serves as a distinct center of collaboration where Avantor can provide broad contract research capabilities covering gene to protein expression, as well as final formulation and drug delivery




Medifirst Solutions Signs Professional Football Player Jordan Poyer as Spokesperson for the Time Machine Laser

Tue, 18 Jul 2017 10:10:46 EDT

FREEHOLD, NJ--(Marketwired - Jul 18, 2017) - MEDIFIRST SOLUTIONS, INC. (OTC PINK: MFST) (the "Company" or "Medifirst"), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device, is pleased to announce that it has signed NFL player Jordan Poyer as a spokesperson for the Time Machine Laser.




Rich Pharmaceuticals Announces Collaboration Agreement To Support The Development of Treatments For Parkinson's Disease

Tue, 18 Jul 2017 09:45:00 EDT

Company Will Receive Cash and Stock and Plans to Pay One Third of the Shares Received in a Dividend to Shareholders




Canna Consumer Goods Evolves into The Premier Canna Broadcasting Media Company; Loudmouth News Radio Success Fuels Expansion

Tue, 18 Jul 2017 09:00:00 EDT

SEATTLE, WA--(Marketwired - Jul 18, 2017) - It is with immense pride that I am able to announce that Canna Consumer Goods (OTC PINK: CBMJ) has evolved into a multi-tier media production, broadcasting, and placement company catering to the cannabis industry.




CV Sciences, Inc. to Exhibit and Present at the Mid-American Health Organization Expo and Summer Splash 2017 Convention

Tue, 18 Jul 2017 08:45:00 EDT

Company Continues its Expansion, Education, and Placement of its Leading Hemp-Derived Supplement Brand, PlusCBD Oil(TM), in the Natural Products Industry




Propanc Biopharma Announces Joint Research Partnership with Jaen University, Spain

Tue, 18 Jul 2017 08:30:00 EDT

MELBOURNE, AUSTRALIA--(Marketwired - July 18, 2017) - Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced the establishment of a 4 year joint research partnership with the Jaén University, based in Andalucía, Spain. The primary objective of the partnership is to expand Propanc Biopharma's product pipeline, by discovering new compounds based on the mode of action of naturally derived proenzymes, trypsinogen and chymotrypsinogen, which are the key active ingredients in the Company's lead product, PRP.




Dewmar International BMC, Inc. (DEWM) Files Provisional Patent to Treat Lung Cancer with Cannabinoids

Tue, 18 Jul 2017 08:13:56 EDT

BATON ROUGE, LA--(Marketwired - Jul 18, 2017) -  Dewmar International BMC, Inc.  (OTC PINK: DEWM) announced today that it has filed a provisional patent with the United States Patent and Trademark Office for the treatment of lung cancer with cannabinoids. The title of the provisional patent filing is Cannabinoid Formulation to Treat Lung Cancer.




Cancer as a Chronic Disease: The Past, the Present and the Future of Cancer Research

Tue, 18 Jul 2017 08:00:00 EDT

This Xtalks webinar, conducted by one of the US's foremost cancer researchers, Dr. Lee Schwartzberg, of the West Cancer Centre and Scientific Leader at George Clinical, will discuss cancer as a chronic disease and how researching cancer under this new archetype is adjusting the way in which clinical oncology trials are conducted and how cancer patients are treated




Advanced Proteome Therapeutics Announces Collaboration to Develop Cancer Therapeutic

Tue, 18 Jul 2017 08:00:00 EDT

VANCOUVER, BC--(Marketwired - July 18, 2017) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8) a biotechnology company focused on developing superior targeted protein therapeutics is pleased to announce a collaboration with the National Research Council of Canada (NRC). Through this arrangement both parties have forged a strategic relationship to further the development of antibody-drug conjugates (ADCs).




Into the Great Wide Open: PTC's transformation & Global Journey to Bring Patients a First Ever Rare Disease Therapy, New Webinar Hosted by Xtalks

Tue, 18 Jul 2017 07:30:00 EDT

TORONTO, ON--(Marketwired - July 18, 2017) - The rare disease biopharmaceutical landscape continues to evolve, but despite the advances made, only five percent of an estimated 7,000 rare diseases have an available treatment option. As life sciences companies begin to address the significant unmet need in the rare disease space, clinical-stage companies developing treatments for rare diseases face a number of challenges as they aim to bring products to market, particularly when on the global scale.




Moleculin Signs Agreement with MD Anderson Cancer Center for Leukemia Drug, Annamycin

Tue, 18 Jul 2017 07:30:00 EDT

HOUSTON, TX--(Marketwired - July 18, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has signed a new technology license agreement with MD Anderson Cancer Center based on new patent applications it intends to file relating to its drug Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML).




Medigus and Golden Grand Expand Distribution Arrangement in China for $27M of MUSE Systems

Tue, 18 Jul 2017 07:00:00 EDT

OMER, ISRAEL--(Marketwired - Jul 18, 2017) - Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced that the Chinese exclusive distribution agreement with Golden Grand (Shanghai Golden Grand-Medical Instruments Ltd.) has been expanded to account for the increased interest in Medigus Ultrasonic Surgical Endostapler (MUSET) systems in China.




Vernalis PLC: Year-End Trading Update and Notice of Full Year Results

Tue, 18 Jul 2017 02:00:00 EDT

WINNERSH, UNITED KINGDOM--(Marketwired - Jul 18, 2017) - Vernalis PLC (LSE: VER)




Cannabis Science, Inc. Finds Large-Scale Manufacturing and Product Distribution Facility in California and Eyes Nevada Property as Nevada Governor Issues Statement of Emergency Due to Potential Shortage of Cannabis

Mon, 17 Jul 2017 13:44:08 EDT

IRVINE, CA--(Marketwired - Jul 17, 2017) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, has found a California facility ideal for its large-scale manufacturing and product distribution center as it ramps up its efforts to supply cannabinoid medications in high-demand by self-medicating patients. As Nevada's Governor issues a Statement of Emergency due to the potential of limited cannabis availability, CBIS is actively looking for a similar facility in Nevada.




Advantis Corp. Ready for Ginos Roasters Product Launch

Mon, 17 Jul 2017 09:00:00 EDT

NEWPORT BEACH, CA--(Marketwired - Jul 17, 2017) - ADVANTIS CORPORATION (OTC PINK: ADVT) is prepared for the upcoming launch of Gino's Roasters pre-rolled joints later this month.




First Harvest Engages Hayden IR and Slee 3 Consulting to Develop Comprehensive Investor Relations Program

Mon, 17 Jul 2017 08:30:00 EDT

Focused on Increasing Awareness and Enhancing Shareholder Value




NEMUS Bioscience Announces NB2222 Pain and Anti-Addiction Data Accepted for Presentation at Upcoming Society of Neuroscience Meeting

Mon, 17 Jul 2017 08:30:00 EDT

COSTA MESA, CA--(Marketwired - Jul 17, 2017) - NEMUS Bioscience, Inc. (OTCQB: NMUS) announced that data recently obtained from the company's research and development partner, the University of Mississippi (UM), was accepted for presentation at the 2017 Annual Meeting of the Society of Neuroscience held in Washington, D.C. on November 11th-15th. The data being presented will show the superiority of the NEMUS proprietary analogue of CBD, NB2222, versus plant-derived CBD in ameliorating pain in a validated mouse (murine) model of chemotherapy-induced peripheral neuropathy using an opioid as an active comparator. Additional data will also be presented detailing the anti-addictive potential of NB2222 in an animal model of opioid addiction. The in vivo research was led by Professor Kenneth Sufka of the University of Mississippi based on the molecular cannabinoid discovery work performed by the team at ElSohly Laboratories, Inc. (ELI) in collaboration with the University, spearheaded by Dr. Mahmoud ElSohly, who also holds a faculty appointment at the University.




Medovex Corporation Announces Pricing of $2.69 Million Concurrent Registered Direct Offering and Private Placement

Mon, 17 Jul 2017 08:00:00 EDT

ATLANTA, GA--(Marketwired - Jul 17, 2017) - Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, today announced that on Friday, July 14, 2017, it entered into definitive agreements with investors for the purchase and sale of 2,956,043 shares of common stock at a price of $.91 per share in a registered direct offering and warrants to purchase up to 1,478,022 shares of common stock at an exercise price of $1.15 per share in a concurrent private placement.




AntriaBio Announces $13 Million Close of Private Placement Transaction and Plan to Dose First Patient with AB101 This Month

Mon, 17 Jul 2017 08:00:00 EDT

LOUISVILLE, CO--(Marketwired - July 17, 2017) - AntriaBio, Inc. ("AntriaBio or the "Company") (OTCQB: ANTB), a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with diabetes and metabolic diseases, announced today that it has closed on a total of $13 million as part of a planned private placement transaction. Under the terms of the financing, accredited investors paid $1.00 for one share of common stock.




How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology

Mon, 17 Jul 2017 07:30:00 EDT

In this new webinar hosted by Xtalks, the presenters will share both design and methodology guidance in Non-GLP Toxicology studies in translational models. The session will guide viewers in how to design the most optimal study to provide the greatest opportunity to generate robust, high-quality data, that gives maximum confidence to select new drug candidates and regulatory submissions.




Premier Biomedical, Inc. CEO Letter July 2017

Mon, 17 Jul 2017 07:00:00 EDT

EL PASO, TX--(Marketwired - Jul 17, 2017) - Greetings From The CEO and Staff at Premier Biomedical (OTCQB: BIEI)




mCig Broadens Construction Project Portfolio and Expands Cannabis Supply Division to the California Market

Mon, 17 Jul 2017 07:00:00 EDT

mCig Updates: Grow Contractors Projects, Supply Division Sales, and Expansion to California Markets




Medifirst Solutions Answers Questions From Shareholders

Fri, 14 Jul 2017 13:10:51 EDT

FREEHOLD, NJ--(Marketwired - Jul 14, 2017) - MEDIFIRST SOLUTIONS, INC. (OTC PINK: MFST) (the "Company" or "Medifirst") would like to update shareholders in a Q&A format regarding the status of current sales and operations in connection with its FDA-cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The following questions were selected because they represent the most common questions asked.




Mega Bridge, Inc. Announces Name Change to HypGen, Inc. and New Strategic Direction

Fri, 14 Jul 2017 09:30:00 EDT

NEW YORK, NY--(Marketwired - Jul 14, 2017) - Mega Bridge, Inc. (OTCQB: MGBR) announced today that it is planning to change its name from Mega Bridge, Inc. to HypGen, Inc. ("HypGen") HypGen intends to focus its efforts on developing therapeutic treatment options for Parkinson's disease. To spearhead this new strategic direction, HypGen's shareholders have elected Dr. McCoy L. Moretz as the new Chief Executive Officer, Chief Financial Officer, Chief Medical Officer and Chairman of the Board of Directors. Richard Chang has also been appointed to the Board of Directors.




The Joint Commission Introduces Revised Pain Assessment and Management Standards, for Accredited Hospitals, to Include Use of Non-Pharmacologic Treatments and Strategies

Thu, 13 Jul 2017 13:55:10 EDT

The National Certification Commission for Acupuncture and Oriental Medicine (NCCAOM)(R) Stresses Importance of Including Nondrug Approaches Administered by Licensed Independent Practitioners for Pain Management